Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SYRE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSpyre expands SPY003 license to all therapeutic uses, but faces dosing delays until 2030
Filed June 1, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
high
SPY003 license field expanded from inflammatory bowel disease only to all therapeutic, prophylactic, palliative and diagnostic uses, significantly broadening commercial potential across multiple indications.
Item 1.01 view on EDGAR → -
high
Company cannot dose patients in clinical trials outside IBD until June 2028 for combination therapy or June 2030 for monotherapy, delaying ability to exploit expanded rights for 2-4 years.
Item 1.01 view on EDGAR → -
medium
Change of control provision accelerates timeline: if Spyre is acquired or completes material transaction, monotherapy dosing restriction terminates by June 2028 instead of 2030.
Item 1.01 view on EDGAR → -
medium
Amendment modifies February 2025 license agreement with Paragon Therapeutics for SPY003, an IL-23 targeted therapeutic asset.
Item 1.01 view on EDGAR →
Summary
Spyre Therapeutics secured a major expansion of its SPY003 license rights on May 29, 2026, transforming the asset from an inflammatory bowel disease-only program into a platform with potential across all therapeutic uses. This amendment with Paragon Therapeutics removes the previous field restriction, opening doors to pursue SPY003 in multiple indications beyond IBD.
However, the expanded rights come with significant timing constraints. Spyre cannot begin dosing patients outside IBD in combination trials until mid-2028 or in monotherapy trials until mid-2030. This creates a 2-4 year waiting period before the company can fully capitalize on the broader license.
The change of control provision is notable: if Spyre is acquired, the monotherapy restriction drops away by 2028, potentially making the company more attractive to acquirers who want faster access to the expanded field. Investors should watch for any updates on Spyre's IBD clinical program timeline and whether management signals acquisition interest. The dosing restrictions mean near-term value depends heavily on IBD progress, while the expanded field represents longer-term optionality that won't materialize until the end of the decade unless a transaction occurs.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
In the event the Company or a licensee of Paragon's retained rights under the SPY003 License Agreement consummates a material transaction, including a change of control of the Company or such licensee, then any remaining restrictions outside of the initial definition of "Field" set forth in the Monotherapy Dosing Restriction shall remain in effect only until June 1, 2028 and thereafter terminate and be of no further force or effect.
If Spyre undergoes a change of control or other material transaction, the dosing restrictions would accelerate and terminate by June 2028 instead of 2030. This provision could make the company more attractive for acquisition by removing the monotherapy restriction earlier.
Event · Item 9.01 — Financial Statements and Exhibits
Spyre Therapeutics amended its IL-23 (SPY003) license agreement on May 29, 2026.
Added in current filing · verify on EDGAR →
First Amendment to Amended and Restated IL-23 (SPY003) License Agreement, dated May 29, 2026.
Spyre Therapeutics executed a first amendment to its existing license agreement for IL-23 (SPY003) on May 29, 2026. The 8-K does not disclose the specific terms or changes made by this amendment, only that it was entered into and filed as an exhibit.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify